{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:00:10Z","timestamp":1790848810697,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As a clinical vaccine platform, lipid nanoparticle (LNP)-formulated mRNA has demonstrated potent and broad antibody responses, prompting speculation about its potential for antibody discovery. Membrane proteins remain among the most challenging targets for antibody development, highlighting the urgent need for technologies that preserve their native conformation during immunization and screening. Nanobodies (VHHs), the single-domain fragments of heavy-chain-only antibodies naturally found in camelids, offer unique advantages over conventional antibodies, including high solubility, stability, and the ability to access cryptic or membrane-proximal epitopes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we report the first demonstration of target specific VHH discovery in a llama using an mRNA\u2013LNP immunization platform. A llama was immunized with LNPs encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 spike protein, a well-characterized model antigen. The resulting immune VHH library was screened using a cell-based panning strategy that maintains antigen conformation and enables recovery of binders recognizing native epitopes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This approach yielded multiple high-affinity spike-specific VHHs, including two clones that effectively blocked the spike\u2013angiotensin-converting enzyme 2 interaction in a surrogate cell-based assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate the feasibility of mRNA\u2013LNP immunization as a rapid and efficient method for isolating target specific, functionally promising VHHs from camelids. When combined with conformationally relevant screening, this platform may provide a versatile and accelerated route for generating high-quality VHHs against complex or recalcitrant targets, particularly membrane proteins, thereby expanding the potential of VHH-based therapeutics and diagnostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag033","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:48:03Z","timestamp":1781092083000},"page":"480-494","source":"Crossref","is-referenced-by-count":0,"title":["Llama mRNA-LNP immunization enables rapid isolation of target specific nanobodies using cell-based panning"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-854X","authenticated-orcid":false,"given":"Kasandra","family":"B\u00e9langer","sequence":"first","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Callaghan","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Renner","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiva","family":"Azizi","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Hu","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Raphael","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Goneau","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hussack","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"McCluskie","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-7193","authenticated-orcid":false,"given":"Bassel","family":"Akache","sequence":"additional","affiliation":[{"name":"Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada , Ottawa, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026100105272245000_ref1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","article-title":"Nanobodies as therapeutics: big opportunities for small antibodies","volume":"21","author":"Steeland","year":"2016","journal-title":"Drug Discov Today"},{"key":"2026100105272245000_ref2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"2026100105272245000_ref3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.tips.2014.03.003","article-title":"GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics","volume":"35","author":"Mujic-Delic","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"2026100105272245000_ref4","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J"},{"key":"2026100105272245000_ref5","doi-asserted-by":"publisher","first-page":"1110541","DOI":"10.3389\/fmicb.2023.1110541","article-title":"Structure-guided design of a potent Clostridiodes difficile toxin A inhibitor","volume":"14","author":"Hussack","year":"2023","journal-title":"Front Microbiol"},{"key":"2026100105272245000_ref6","doi-asserted-by":"publisher","first-page":"2613548","DOI":"10.1080\/19420862.2026.2613548","article-title":"The making of multispecific immunoglobulins - a clinical perspective","volume":"18","author":"Brinkmann","year":"2026","journal-title":"MAbs"},{"key":"2026100105272245000_ref7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcp.2012.08.021","article-title":"Opportunities for functional selectivity in GPCR antibodies","volume":"85","author":"Webb","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2026100105272245000_ref8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4161\/mabs.2.6.13420","article-title":"Therapeutic antibodies directed at G protein-coupled receptors","volume":"2","author":"Hutchings","year":"2010","journal-title":"MAbs"},{"key":"2026100105272245000_ref9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrd.2017.173","article-title":"Opportunities for therapeutic antibodies directed at G-protein-coupled receptors","volume":"16","author":"Hutchings","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026100105272245000_ref10","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1093\/nar\/gkq789","article-title":"By-passing in vitro screening--next generation sequencing technologies applied to antibody display and in silico candidate selection","volume":"38","author":"Ravn","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2026100105272245000_ref11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.mie.2016.10.029","article-title":"Screening and characterization strategies for Nanobodies targeting membrane proteins","volume":"584","author":"Veugelen","year":"2017","journal-title":"Methods Enzymol"},{"key":"2026100105272245000_ref12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-61779-968-6_6","article-title":"Selection by phage display of single domain antibodies specific to antigens in their native conformation","volume":"911","author":"Verheesen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2026100105272245000_ref13","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3389\/fimmu.2017.01989","article-title":"A cDNA immunization strategy to generate nanobodies against membrane proteins in native conformation","volume":"8","author":"Eden","year":"2017","journal-title":"Front Immunol"},{"key":"2026100105272245000_ref14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/hum.2018.077","article-title":"Using DNA immunization to elicit monoclonal antibodies in mice, rabbits, and humans","volume":"29","author":"Liu","year":"2018","journal-title":"Hum Gene Ther"},{"key":"2026100105272245000_ref15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/vaccines13060601","article-title":"mRNA vaccine technology beyond COVID-19","volume":"13","author":"Oloruntimehin","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026100105272245000_ref16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0264-410X(02)00574-1","article-title":"Induction of immune responses by DNA vaccines in large animals","volume":"21","author":"Babiuk","year":"2003","journal-title":"Vaccine"},{"key":"2026100105272245000_ref17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41541-022-00581-y","article-title":"A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines","volume":"7","author":"Gomez","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2026100105272245000_ref18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1080\/21505594.2017.1307485","article-title":"Rapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application","volume":"8","author":"Lankelma","year":"2017","journal-title":"Virulence"},{"key":"2026100105272245000_ref19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1479-0556-6-4","article-title":"DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants","volume":"6","author":"Pokorna","year":"2008","journal-title":"Genet Vaccines Ther"},{"key":"2026100105272245000_ref20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00262-017-2006-y","article-title":"HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia","volume":"66","author":"Samuels","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2026100105272245000_ref21","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1016\/j.vaccine.2008.03.091","article-title":"Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates","volume":"26","author":"Verstrepen","year":"2008","journal-title":"Vaccine"},{"key":"2026100105272245000_ref22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/gt.2014.87","article-title":"Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection","volume":"21","author":"Wagemakers","year":"2014","journal-title":"Gene Ther"},{"key":"2026100105272245000_ref23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nm1264","article-title":"A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression","volume":"11","author":"Bins","year":"2005","journal-title":"Nat Med"},{"key":"2026100105272245000_ref24","doi-asserted-by":"publisher","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J Biol Chem"},{"key":"2026100105272245000_ref25","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.4049\/jimmunol.1500888","article-title":"Development by genetic immunization of monovalent antibodies (Nanobodies) behaving as antagonists of the human ChemR23 receptor","volume":"196","author":"Peyrassol","year":"2016","journal-title":"J Immunol"},{"key":"2026100105272245000_ref26","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1096\/fj.07-8661com","article-title":"Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo","volume":"21","author":"Koch-Nolte","year":"2007","journal-title":"FASEB J"},{"key":"2026100105272245000_ref27","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","article-title":"Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo","volume":"7","author":"Fumey","year":"2017","journal-title":"Sci Rep"},{"key":"2026100105272245000_ref28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fendo.2018.00153","article-title":"Development by genetic immunization of monovalent antibodies against human vasoactive intestinal peptide receptor 1 (VPAC1), new innovative, and versatile tools to study VPAC1 receptor function","volume":"9","author":"Peyrassol","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026100105272245000_ref29","doi-asserted-by":"publisher","first-page":"366ra162","DOI":"10.1126\/scitranslmed.aaf8463","article-title":"Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation","volume":"8","author":"Danquah","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026100105272245000_ref30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1042\/BCJ20180795","article-title":"Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling","volume":"476","author":"Rossotti","year":"2019","journal-title":"Biochem J"},{"key":"2026100105272245000_ref31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chembiol.2022.12.005","article-title":"RAMIHM generates fully human monoclonal antibodies by rapid mRNA immunization of humanized mice and BCR-seq","volume":"30","author":"Ren","year":"2023","journal-title":"Cell Chem Biol"},{"key":"2026100105272245000_ref32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42003-022-03866-z","article-title":"Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models","volume":"5","author":"Rossotti","year":"2022","journal-title":"Commun Biol"},{"key":"2026100105272245000_ref33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbiotec.2020.12.005","article-title":"Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells","volume":"326","author":"Stuible","year":"2021","journal-title":"J Biotechnol"},{"key":"2026100105272245000_ref34","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1074\/jbc.M110.198754","article-title":"Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain","volume":"286","author":"Hussack","year":"2011","journal-title":"J Biol Chem"},{"key":"2026100105272245000_ref35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s44298-024-00067-9","article-title":"Reduced cross-protective potential of omicron compared to ancestral SARS-CoV-2 spike vaccines against potentially zoonotic coronaviruses","volume":"2","author":"Renner","year":"2024","journal-title":"Npj Viruses"},{"key":"2026100105272245000_ref36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.bbagen.2015.03.009","article-title":"Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells","volume":"1850","author":"Rossotti","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2026100105272245000_ref37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jbiotec.2017.06.009","article-title":"Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch","volume":"255","author":"Poulain","year":"2017","journal-title":"J Biotechnol"},{"key":"2026100105272245000_ref38","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/pro.70114","article-title":"Optimization of synthetic human V(H) affinity and solubility through in vitro affinity maturation and minimal camelization","volume":"34","author":"Belanger","year":"2025","journal-title":"Protein Sci"},{"key":"2026100105272245000_ref39","doi-asserted-by":"publisher","first-page":"2 17 11","DOI":"10.1002\/0471142735.im0217s103","article-title":"Single-domain antibodies and their utility","volume":"103","author":"Baral","year":"2013","journal-title":"Curr Protoc Immunol"},{"key":"2026100105272245000_ref40","doi-asserted-by":"publisher","DOI":"10.3390\/mps8050104","article-title":"A safe and accessible cell-based spike-ACE2 binding assay for evaluating SARS-CoV-2 neutralization activity in biological samples using flow cytometry","volume":"8","author":"Rossotti","year":"2025","journal-title":"Methods Protoc"},{"key":"2026100105272245000_ref41","doi-asserted-by":"publisher","first-page":"e3001384","DOI":"10.1371\/journal.pbio.3001384","article-title":"Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus","volume":"19","author":"Amanat","year":"2021","journal-title":"PLoS Biol"},{"key":"2026100105272245000_ref42","doi-asserted-by":"publisher","first-page":"789427","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of Pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026100105272245000_ref43","doi-asserted-by":"publisher","first-page":"1951426","DOI":"10.1080\/19420862.2021.1951426","article-title":"Highly sensitive detection of antibody nonspecific interactions using flow cytometry","volume":"13","author":"Makowski","year":"2021","journal-title":"MAbs"},{"key":"2026100105272245000_ref44","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/19420862.2016.1189050","article-title":"DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops","volume":"8","author":"Woning","year":"2016","journal-title":"MAbs"},{"key":"2026100105272245000_ref45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymeth.2013.03.001","article-title":"Deep sequencing of phage display libraries to support antibody discovery","volume":"60","author":"Ravn","year":"2013","journal-title":"Methods"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag033\/68513081\/tbag033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/480\/68513081\/tbag033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/480\/68513081\/tbag033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:27:29Z","timestamp":1790846849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/4\/480\/8706322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag033","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,11]]}}}